Lars Kongsbak
Director/Board Member bei VIROGATES A/S
Vermögen: 6 571 $ am 31.03.2024
Profil
Lars Kongsbak is currently the President & Chief Executive Officer at Samplix ApS since 2017.
He is also an Independent Director at ViroGates A and BlueBee Holding BV, both since 2017.
Previously, Dr. Kongsbak served as the President & Chief Executive Officer at Exiqon A from 2003 to 2016.
He holds a doctorate degree from the Technical University of Denmark, conferred in 1990, and a graduate degree from the University of Copenhagen, conferred in 1988.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VIROGATES A/S
0,11% | 31.12.2023 | 6 968 ( 0,11% ) | 6 571 $ | 31.03.2024 |
Aktive Positionen von Lars Kongsbak
| Unternehmen | Position | Beginn |
|---|---|---|
| VIROGATES A/S | Director/Board Member | - |
BlueBee Holding BV
 BlueBee Holding BV Medical SpecialtiesHealth Technology Bluebee Holding BV engages in the development of a private cloud-based accelerated genomics platform. It supports cross-functional teams of life science researchers and clinicians by effectively centralizing and managing their genomics data processes and storage needs. The company was founded in 2011 by Vlad-Mihai Sima, Koen Bertls, Luk Wayne, and Zaid Al-Ars and is headquartered in Rijswijk, the Netherlands. | Director/Board Member | 08.05.2017 |
Samplix ApS
 Samplix ApS BiotechnologyHealth Technology Samplix ApS provides technology for enrichment of deoxyribonucleic acid samples. Its PINS technology enables enrichment of deoxyribonucleic acid or ribonucleic acid targets from extremely complex and low abundance samples such as environment, blood, or biopsy samples. The company was founded in 2013 and is headquartered in Herlev, Denmark. | Chief Executive Officer | 01.11.2017 |
Ehemalige bekannte Positionen von Lars Kongsbak
| Unternehmen | Position | Ende |
|---|---|---|
| EXIQON A/S | Chief Executive Officer | 01.10.2016 |
Ausbildung von Lars Kongsbak
| Technical University of Denmark | Doctorate Degree |
| University of Copenhagen | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIROGATES A/S | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Exiqon A/S
 Exiqon A/S Miscellaneous Commercial ServicesCommercial Services Exiqon A/S engages in the development of solutions for ribonucleic acid research and analysis through its Locked Nucleic Acid proprietary technology. Its products and services are used by researchers in academia, biotech, and pharmaceutical companies around the world to make discoveries about the correlation between gene activity and the development of disease. The company was founded by Mikael Ørum, Henrik Ørum and Troels Koch on November 1, 1995 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Samplix ApS
Samplix ApS BiotechnologyHealth Technology Samplix ApS provides technology for enrichment of deoxyribonucleic acid samples. Its PINS technology enables enrichment of deoxyribonucleic acid or ribonucleic acid targets from extremely complex and low abundance samples such as environment, blood, or biopsy samples. The company was founded in 2013 and is headquartered in Herlev, Denmark. | Health Technology |
BlueBee Holding BV
BlueBee Holding BV Medical SpecialtiesHealth Technology Bluebee Holding BV engages in the development of a private cloud-based accelerated genomics platform. It supports cross-functional teams of life science researchers and clinicians by effectively centralizing and managing their genomics data processes and storage needs. The company was founded in 2011 by Vlad-Mihai Sima, Koen Bertls, Luk Wayne, and Zaid Al-Ars and is headquartered in Rijswijk, the Netherlands. | Health Technology |
